Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;183(7):2995-2999.
doi: 10.1007/s00431-024-05546-y. Epub 2024 Apr 18.

Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome?

Marika Pane  1   2 , Giulia Stanca  1 , Chiara Ticci  3 , Costanza Cutrona  1   2 , Roberto De Sanctis  1   2 , Matteo Pirinu  4 , Giorgia Coratti  1   2 , Concetta Palermo  1 , Beatrice Berti  1 , Daniela Leone  1 , Michele Sacchini  3 , Margherita Cerboneschi  4 , Lavinia Fanelli  1   2 , Giulia Norcia  1 , Nicola Forcina  1 , Anna Capasso  1   2 , Gianpaolo Cicala  1   2 , Laura Antonaci  1 , Martina Ricci  1   2 , Maria Carmela Pera  1   2 , Chiara Bravetti  1   2 , Maria Alice Donati  3 , Elena Procopio  3 , Emanuela Abiusi  5 , Alessandro Vaisfeld  5 , Roberta Onesimo  6 , Francesco Danilo Tiziano  5 , Eugenio Mercuri  7   8
Affiliations

Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome?

Marika Pane et al. Eur J Pediatr. 2024 Jul.

Abstract

Neonatal screening for SMA has allowed the identification of infants who may present with early clinical signs. Our aim was to establish whether the presence and the severity of early clinical signs have an effect on the development of motor milestones. Infants identified through newborn screening were prospectively assessed using a structured neonatal neurological examination and an additional module developed for the assessment of floppy infants. As part of the follow-up, all infants were assessed using the HINE-2 to establish developmental milestones. Only infants with at least 24 months of follow-up were included. Normal early neurological examination (n = 11) was associated with independent walking before the age of 18 months while infants with early clinical signs of SMA (n = 4) did not achieve ambulation (duration follow-up 33.2 months). Paucisymptomatic patients (n = 3) achieved ambulation, one before the age of 18 months and the other 2 between 22 and 24 months. Conclusion: Our findings suggest that early clinical signs may contribute to predict motor milestones development. What is Known: • There is increasing evidence of heterogeneity among the SMA newborns identified via NBS. • The proposed nosology describes a clinically silent disease, an intermediate category ('paucisymptomatic') and 'symptomatic SMA'. What is New: • The presence of minimal clinical signs at birth does not prevent the possibility to achieve independent walking but this may occur with some delay. • The combination of genotype at SMN locus and clinical evaluation may better predict the possibility to achieve milestones.

Keywords: Floppy infant module; Neonatal neurological examination; Newborn screening; SMA.

PubMed Disclaimer

Conflict of interest statement

G.Cor and MCP report personal fees from BIOGEN S.R.L., ROCHE and NOVARTIS outside the submitted work. MP is part of advisory boards for BIOGEN S.R.L., ROCHE, AVEXIS and NOVARTIS; EM is part of advisory board for BIOGEN S.R.L., ROCHE, AVEXIS and NOVARTIS, Scholar ROCK, EPIRIUM, CYTOKINETICS and NMD PHARMA. The remaining authors have nothing to disclose.

Figures

Fig. 1
Fig. 1
Details of the milestones achieved and of treatment
See this image and copyright information in PMC

References

    1. Dangouloff T, Vrscaj E, Servais L, Osredkar D, Group SNWS Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go. Neuromuscul Disord. 2021;31:574–582. doi: 10.1016/j.nmd.2021.03.007. - DOI - PubMed
    1. Finkel RS, Benatar M. Pre-symptomatic spinal muscular atrophy: a proposed nosology. Brain. 2022;145:2247–2249. doi: 10.1093/brain/awac125. - DOI - PubMed
    1. Pane M, Donati MA, Cutrona C, De Sanctis R, Pirinu M, Coratti G, Ricci M, Palermo C, Berti B, Leone D, Ticci C, Sacchini M, Cerboneschi M, Capasso A, Cicala G, Pera MC, Bravetti C, Abiusi E, Vaisfeld A, Vento G, Tiziano FD, Mercuri E. Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening. Eur J Pediatr. 2022;181:2821–2829. doi: 10.1007/s00431-022-04470-3. - DOI - PMC - PubMed
    1. Crawford TO, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, Kirschner J, et al. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve. 2023;68:157–170. doi: 10.1002/mus.27853. - DOI - PubMed
    1. Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, McMillan HJ, Finkel RS, Swoboda KJ, Kwon JM, Zaidman CM, Chiriboga CA, Iannaccone ST, Krueger JM, Parsons JA, Shieh PB, Kavanagh S, Wigderson M, Tauscher-Wisniewski S, McGill BE, Macek TA. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1390–1397. doi: 10.1038/s41591-022-01867-3. - DOI - PMC - PubMed